Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.

Area of Science:

• Immunology
• Pharmacology

Background:

• The neonatal fragment crystallizable (Fc) receptor (FcRn) is crucial for recycling IgG and albumin, extending their circulation time.
• FcRn inhibitors are emerging therapies targeting IgG recycling for autoimmune and hematologic conditions.

Purpose of the Study:

• To review current data on FcRn inhibitors, including clinical trial results, safety, and mechanisms of action.
• To compare FcRn inhibition with other IgG-depleting methods and discuss implications for autoimmune diseases.
• To provide practical guidance on managing infection risks associated with FcRn inhibition.

Main Methods:

• Review of clinical trial data for FcRn inhibitors (activity, safety, mechanism).
• Analysis of alternative IgG removal procedures (plasmapheresis, immunoadsorption).
• Examination of diseases with IgG loss and immunodeficiencies with mechanistic parallels.

Main Results:

• FcRn inhibitors accelerate IgG destruction, reducing pathogenic IgG and immune complexes.
• These inhibitors are expected to have no adverse effects on IgA, IgM, IgE, complement, or immune cells.
• Potential for broad application in antibody-mediated autoimmune diseases is indicated.

Conclusions:

• FcRn inhibitors represent a novel therapeutic approach with significant potential in autoimmune diseases.
• Understanding and mitigating infection risks is crucial for clinical implementation.
• Further research is needed to fully elucidate the long-term effects and applications of FcRn inhibition.